BioStock: Chordate Medical’s migraine treatment gets attention at congress

Recently, medtech company Chordate Medical participated in the prominent pain congress Deutsche Schmerzkongress in Mannheim, Germany. During the event, they experienced an increased interest in their migraine treatment Ozilia Migraine. This positive reception is expected to strengthen the company’s ongoing marketing activities in Germany, where they previously also conducted a successful patient study. To find out more about the market introduction in Germany and the highlights from the congress, BioStock contacted the company’s CEO Anders Weilandt. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/10/chordate-medicals-migraine-treatment-gets-attention-at-congress/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se